Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN

Explore this article's sources with AI

ChatGPTClaudePerplexityGeminiGrokGoogle AI

Follow PeptideMethods on Google

First published

Food-Derived Peptides in Obese Rodents

NDP-35 and NDP-45 changed satiety hormones and body weight in rodent models, but no human trial has established efficacy or safety.

Why we wrote this. The semaglutide comparator invites a human-treatment comparison that this animal paper cannot support.

In this article (5 sections)
  1. What NDP-35 and NDP-45 are
  2. The receptor and hormone findings
  3. The 28-day rat experiment
  4. What the safety observations mean
  5. What we do not yet know

A 2026 preclinical paper reports that two food-protein-derived peptides changed satiety hormones and reduced food intake and body weight in rodent models. The lead candidate, NDP-35, was compared with injected semaglutide in one rat experiment. The results do not show that either peptide works in people or that it matches semaglutide as a treatment[1].

What NDP-35 and NDP-45 are

The researchers used an AI-guided screen of common food proteins to identify sequences native to edible proteins, then reproduced selected sequences synthetically. NDP-35 came from Coffea arabica protein and NDP-45 from banana protein[2]. Calling them nature-derived describes the source sequence. It does not mean that the experimental material was simply coffee or banana.

The proposed strategy differs from a peptide medicine engineered for systemic exposure. These candidates were intended to act locally at the gut epithelium, the tissue lining the intestine. The aim was to engage nutrient-sensing receptors on enteroendocrine L cells, which release hormones after food reaches the gut.

The receptor and hormone findings

In the reported assays, NDP-35 acted as a selective agonist at GPR40, a receptor involved in nutrient sensing. Its half-maximal effective concentration was 32.7 nanomolar[1]. That laboratory potency describes activity in the assay used by the investigators. It does not establish an effective human oral dose.

In mice, NDP-35 increased plasma GLP-1, GIP and PYY while reducing hormones the authors described as hunger-related[2]. These are short-term biological endpoints. A hormone response can support a proposed mechanism, but it is not the same as demonstrating durable weight loss, health benefit or acceptable long-term safety.

The paper's language about reproducing a meal-like hormone response should also remain within the model tested. Meals contain many nutrients and produce neural, mechanical and metabolic signals beyond the measured hormones. The abstract does not establish that the peptides reproduce the full physiology of eating.

The 28-day rat experiment

Diet-induced obese rats received oral NDP-35 for 28 days. The abstract reports reduced food intake and about 5% lower body weight, compared with an approximately 3% gain in vehicle-treated animals[1]. Vehicle is the inactive preparation used to deliver the experimental material.

A subcutaneous semaglutide arm served as a reference comparator, and the authors say endpoint values were of similar magnitude[2]. This does not establish equivalence. The compounds used different routes, and the abstract does not describe an equivalence margin or a statistical test designed to show that NDP-35 was no worse than semaglutide.

EMA identifies Wegovy as an authorized semaglutide medicine for weight management in specified human populations[3]. NDP-35 and NDP-45 remain preclinical candidates in the cited paper. The semaglutide arm helps readers interpret one animal experiment, but it does not transfer semaglutide's human evidence or regulatory status to the new peptides.

What the safety observations mean

The authors report no treatment-related changes in terminal clinical chemistry or organ-weight markers over the dosing period[1]. Terminal means the measurements were taken at the end of the experiment. These findings are limited to the selected markers, species, study conditions and 28-day duration.

A clean set of short animal measurements cannot rule out uncommon toxicity, effects that require longer exposure, interactions with medicines or human-specific reactions. It also does not answer whether an orally administered peptide remains stable, reaches the intended site consistently or produces the same receptor activity in people.

The structurally different NDP-45 reportedly reproduced the hormonal and weight-related effects[2]. Replication with a second sequence makes the proposed approach more interesting, but both candidates were assessed within the same preclinical research program. Independent replication is not described in the abstract.

Animal body-weight experiments can be sensitive to housing, diet, stress and how food intake is measured. The abstract does not provide group sizes, randomization procedures, blinding details or a full table of adverse observations. Those details may appear in the subscription article, but they cannot be supplied from the public record inspected for this readout.

Route matters too. Oral delivery is part of the candidate's proposed advantage, while the semaglutide reference arm was injected under the skin. Similar endpoint values after different routes do not identify equal potency, equal exposure or equal tolerability. They answer a narrower question about what happened in that experiment. Nothing more.

What we do not yet know

No human participants were studied. The public abstract provides no human pharmacokinetics, tolerability data, dose-ranging results or randomized clinical outcomes. It also does not establish whether either peptide can be manufactured as a consistent oral product that remains active through storage and digestion.

The next evidence steps would include fuller toxicology, formulation work and carefully staged human research if regulators permit it. Until then, these results belong in preclinical discovery. Readers looking for established human evidence can use our semaglutide research overview without treating NDP-35 as an alternative medicine.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.

Frequently asked

Has NDP-35 been tested for weight loss in people?

No human trial is reported in the cited paper. Its hormone and body-weight findings came from mouse and rat experiments.

Did NDP-35 perform as well as semaglutide?

The authors reported endpoint values of similar magnitude in one rat experiment. The study was not a human head-to-head trial and did not establish clinical equivalence.

Does nature-derived mean the test material was ordinary food?

No. The sequences were identified in edible proteins and then reproduced synthetically for research. The experiments tested defined peptides, not coffee or banana as foods.

Sources

  1. [1]Abramov M et al. A Nature-Derived Peptide Promotes Satiety Hormone Response and Weight Loss In Vivo. 2026. PMID 42989960Tier 1 · primary↩
  2. [2]Europe PMC indexed abstract record for PMID 42989960Tier 1 · primary↩
  3. [3]EMA medicine overview for Wegovy (semaglutide)Tier 1 · primary↩

No revisions yet. First published .

About the editorial team

PeptideMethods is written and edited by the PeptideMethods Editorial Team and published by Digital Compass Group Ltd. The team is not made up of medical professionals; every health, regulatory or dosage claim on the site is tied to a primary source and is not a substitute for advice from a qualified clinician.

See our editorial policy and methodology for how we research, source and verify.